Third-line Treatment of Gefitinib in NSCLC Patients

Summary

The purpose of this study is to evaluate the disease control rate (DCR) of gefitinib as third-line retreatment in stage IIIB/IV NSCLC with EGFR 19del/L858R positive mutation patients who had benefited from first-line gefitinib treatment with EGFR 19del/L858R positive mutation and tumor progression after the second-line chemotherapy

Timeline

Start

2014-04-07

Primary completion

2017-04-10

Completion

2018-04-10

Drugs

Indications